During the past decade, Schiff Center for Liver Diseases/University of Miami conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 32 clinical trials were completed, i.e. on average, 58.2% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 23 clinical trials were completed. i.e. 127.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Schiff Center for Liver Diseases/University of Miami" #1 sponsor was "Gilead Sciences" with 17 trials, followed by "Bristol-Myers Squibb" with 7 trials sponsored, "CymaBay Therapeutics, Inc." with 6 trials sponsored, "Intercept Pharmaceuticals" with 6 trials sponsored and "Target PharmaSolutions, Inc." with 6 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Schiff Center for Liver Diseases/University of Miami" #1 collaborator was "AbbVie" with 2 trials as a collaborator, "Bausch Health Americas, Inc." with 1 trials as a collaborator, "BioIncept LLC" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Novo Nordisk A/S" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Schiff Center for Liver Diseases/University of Miami" are "Hepatitis C" (9 trials), "Nonalcoholic Steatohepatitis" (9 trials), "Primary Biliary Cholangitis" (6 trials), "Chronic Hepatitis B" (5 trials) and "Chronic Hepatitis C" (5 trials). Many other conditions were trialed in "Schiff Center for Liver Diseases/University of Miami" in a lesser frequency.

Most popular intervention types in "Schiff Center for Liver Diseases/University of Miami" are "Drug" (66 trials), "Biological" (5 trials), "Other" (4 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Ribavirin" (7 trials), "Daclatasvir" (4 trials), "RBV" (4 trials) and "Sofosbuvir" (4 trials). Other intervention names were less common.

The vast majority of trials in "Schiff Center for Liver Diseases/University of Miami" are 75 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Schiff Center for Liver Diseases/University of Miami". undefined are not yet recruiting, 11 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 44 completed trials in Schiff Center for Liver Diseases/University of Miami, undefined suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in Schiff Center for Liver Diseases/University of Miami, 4 "Phase 1" clinical trials were conducted, 38 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".